A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
Philip N. Newsome, Kristine Buchholtz, Kenneth Cusi, Martin Linder, Takeshi Okanoue, Vlad Ratziu, Arun J. Sanyal, Anne‐Sophie Sejling, Stephen A. Harrison
Abstract
N Engl J Med 2021; 384:1113–1124. DOI: 10.1056/NEJMoa2028395 https://www.nejm.org/doi/full/10.1056/NEJMoa2028395
Topics & Concepts
Nonalcoholic steatohepatitisSemaglutideMedicinePlaceboInternal medicineDiabetes mellitusEndocrinologyPathologyNonalcoholic fatty liver diseaseFatty liverType 2 diabetesAlternative medicineLiraglutideDiseaseLiver Disease Diagnosis and TreatmentDiabetes Treatment and ManagementMetabolism, Diabetes, and Cancer